The specific G6PDH inhibitory effect of these compounds may be exploited for the treatment of human diseases with high NADPH and GSH consumption rates, including malaria, trypanosomiasis, cancer or obesity. Here, H6PD is linked to obesity due to melanocortin 4 receptor deficiency.